SRC TR - 12 - 077

HPV3 TOXICITY STUDY PLAN REVIEW ( FINAL ) 1 - Propanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1) , CASRN 52556 - 42 - 0 Prepared by: William L. Richards , Teresa Manyin, and Laura Morlacci Defense and Environmental S olutions Division SRC, Inc. 7502 Round Pond Road North Syracuse, NY 13212 Contract No. EP - W - 09 - 027 Task FG007. 3 .009.00 6 Submitted to: OCSPP/OPPT/RAD (7403M) U.S. Environmental Protection Agency 1200 Pennsylvania Avenue

Washington, D.C. 20460 Bryan Lo bar , Project Officer Meena Sonawane, Work Assignment Manager David Brooks, Alternate Work Assignment Manager Octo ber 24 , 201 2HPV3 Study Plan Review ( Final ) CASRN 52556 - 42 - 0

1 HPV3 Toxicity Study Plan Review: 1 - Propanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1), CASRN 52556 - 42 - 0 In response to the test rule, “Testing of Certain High Production Volume Chemicals; Third Group of Chemicals ” , 76 FR 65385 , October 21, 2011 , the COPS - 1 Consortium, a cost - sharing consortium formed and managed under the Society of Chemical Manufacturers an d Affiliates (SOCMA), submitted a study plan on August 29, 2012 for several toxicity tests to be conducted by WIL Research Europe with 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1), CASRN 52556 - 42 - 0 , also known as COPS - 1. 1. General Comments: The test rule classifies 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1), CASRN 52556 - 42 - 0 as a Class 1 Chemical Substance for which testing must be conducted with material having a purit y of 99% or greater. F or toxicity testing, the COPS - 1 Consortium proposes the testing of a “typical commercial product as supplied by a member of the Consortium with details of purity and known properties.” However, information on the expected or known purity of this “typical commercial product ” was not provided i n the August 29, 2012 letter . If the COPS - 1 Consortium believes that a 99% level of purity of 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sod ium salt (1:1) is unattainable for the “typical commercial prod uct” that is proposed for testing, the Consortium may request a modification (see 76 FR 65395). For all toxicity tests, the final study report should include the analyzed composition of the test substance, including identities and concentrations of majo r ingredients and of impurities. 2 . Aquatic Toxicity Under the testing requirement C1 of the test rule, a determination of whether to perform aquatic toxicity testing under Test Group 1 or Test Group 2 is based on a consideration of the log K ow for th e test substance. If log K ow is < 4.2, Test Group 1 testing is required; if log K ow is ≥ 4.2, Test Group 2 testing is required. The August 29, 2012 letter from the COP S - 1 Consortium presented a printout from KOWWIN that provides an estimate d log K ow valu e of - 5.00 for 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sod ium salt (1:1). Based on criter ia of Table 3 (p. 65407) of the test rule , the finding of an estimated log K ow of - 5.00 indicates that testing to determine an experimental log K ow f or 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen 1 - yloxy) - , sod ium salt (1:1) is not required. Therefore, on the basis of the estimated log K ow of - 5.00, EPA approves the COP S - 1 Consortium plan to fulfill the C1 testing requirement for 1 - p ropanesulfonic a cid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sod ium salt (1:1) as a Test Group 1 substance. Pending the COP S - 1 Consortium’s resolution with EPA of the test substance purity/composition issue described under General Comments, above, EPA approves the Consortium’ s plan to conduct the following three aquatic toxicity studies to fulfill the C1 testing requirement for 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sod ium salt (1:1) :HPV3 Study Plan Review ( Final ) CASRN 52556 - 42 - 0

2 1. Acute T oxicity to F ish, ASTM E 729 - 96 (reapproved 2007)/OPPTS 850.10 75 2. Acute Toxicity to Daphnia , ASTM E729 - 96 (reapproved 2007)/OPPTS 850.1010 3. Toxicity to Plants (Algae), ASTM E1218 - 04 ε1 /OPPTS 850.5400 Each tested concentration and endpoint value should be expressed in terms of the concentration of the active i ngredient 1 - propanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1) . 3. Mammalian Toxicity Pending the COP S - 1 Consortium’s resolution with EPA of the test substance purity/composition issue described under General Comments, above, EPA a pproves the Consortium’s plan to conduct the following studies of 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sod ium salt (1:1) to fulfill the Mammalian Toxicity testing requirements of the test rule: 1. An Acute Oral Toxicity

– Up - and - Down Procedure test using 40 CFR 799.9110(d)(1)(i)(A) to fulfill testing requirement D. 2. A Bacterial Reverse Mutation Test using 40 CFR 799.9510 /OECD 471 to fulfill testing requirement E1. 3. An I n vitro Mammalian Chromosom e Aberration Test using 40 CFR 799 .9537 /OECD 473 to fulfill testing requirement E2. 4. A Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test using 40 CFR 799.9365 /OPPTS 870.3650/OECD 422 to fulfill testing requirement F1. Each concentration t ested for the genotoxicity studies required under E1 and E2 should be expressed in terms of the concentration of the active ingredient 1 - propanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1) . Each dose tested and endpoint value for the studies required under D and F1 will be express ed in terms of the dose of the active ingredient . Conclusion: The study plan submitted to fulfill testing requirements C1 (Test Group 1 endpoints), D, E1, E2, and F1 for 1 - p ropanesulfonic acid, 2 - hydroxy - 3 - (2 - propen - 1 - yloxy) - , sodium salt (1:1), CASRN 52556 - 42 - 0 , also known as COPS - 1, is considered adequate with the stipulations listed above.